Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells

作者: Peng Cheng , Emma Phillips , Sung-Hak Kim , David Taylor , Thomas Hielscher

DOI: 10.1016/J.STEMCR.2015.03.005

关键词:

摘要: Glioblastoma is a highly lethal cancer for which novel therapeutics are urgently needed. Two distinct subtypes of glioblastoma stem-like cells (GSCs) were recently identified: mesenchymal (MES) and proneural (PN). To identify mechanisms to target the more aggressive MES GSCs, we combined transcriptomic expression analysis kinome-wide short hairpin RNA screening PN GSCs. In comparison found significant upregulation phosphorylation receptor tyrosine kinase AXL in Knockdown significantly decreased GSC self-renewal capacity vitro inhibited growth patient-derived xenografts. Moreover, inhibition with shRNA or pharmacologic inhibitors also increased cell death Clinically, was elevated GBM subtype correlated poor prognosis multiple cancers. conclusion, identified as potential molecular approaches treat other solid

参考文章(47)
Ichiro Nakano, Harley I. Kornblum, Methods for analysis of brain tumor stem cell and neural stem cell self-renewal. Methods of Molecular Biology. ,vol. 568, pp. 37- 56 ,(2009) , 10.1007/978-1-59745-280-9_4
G. K. Smyth, limma: Linear Models for Microarray Data Springer, New York, NY. pp. 397- 420 ,(2005) , 10.1007/0-387-29362-0_23
Rachel M.A. Linger, Amy K. Keating, H. Shelton Earp, Douglas K. Graham, TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer Advances in Cancer Research. ,vol. 100, pp. 35- 83 ,(2008) , 10.1016/S0065-230X(08)00002-X
Kristina H. Knubel, Ben M. Pernu, Alexandra Sufit, Sarah Nelson, Angela M. Pierce, Amy K. Keating, MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme Oncotarget. ,vol. 5, pp. 1338- 1351 ,(2014) , 10.18632/ONCOTARGET.1793
Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel, Timothy F. Cloughesy, Will Kinase Inhibitors Make it as Glioblastoma Drugs? Therapeutic Kinase Inhibitors. ,vol. 355, pp. 135- 169 ,(2011) , 10.1007/82_2011_178
Melanie Janning, Isabel Ben-Batalla, Sonja Loges, Axl inhibition: a potential road to a novel acute myeloid leukemia therapy? Expert Review of Hematology. ,vol. 8, pp. 135- 138 ,(2015) , 10.1586/17474086.2015.997704
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho, Yun Jung Choi, Chang-Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung-Shin Lee, Vincent A Miller, Maria Arcila, Marc Ladanyi, Philicia Moonsamy, Charles Sawyers, Titus J Boggon, Patrick C Ma, Carlota Costa, Miquel Taron, Rafael Rosell, Balazs Halmos, Trever G Bivona, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nature Genetics. ,vol. 44, pp. 852- 860 ,(2012) , 10.1038/NG.2330
K Vuoriluoto, H Haugen, S Kiviluoto, J-P Mpindi, J Nevo, C Gjerdrum, C Tiron, J B Lorens, J Ivaska, Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer Oncogene. ,vol. 30, pp. 1436- 1448 ,(2011) , 10.1038/ONC.2010.509
V Goidts, J Bageritz, L Puccio, S Nakata, M Zapatka, S Barbus, G Toedt, B Campos, A Korshunov, S Momma, E Van Schaftingen, G Reifenberger, C Herold-Mende, P Lichter, B Radlwimmer, RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival Oncogene. ,vol. 31, pp. 3235- 3243 ,(2012) , 10.1038/ONC.2011.490
Sheila K. Singh, Cynthia Hawkins, Ian D. Clarke, Jeremy A. Squire, Jane Bayani, Takuichiro Hide, R. Mark Henkelman, Michael D. Cusimano, Peter B. Dirks, Identification of human brain tumour initiating cells Nature. ,vol. 432, pp. 396- 401 ,(2004) , 10.1038/NATURE03128